Activation-induced cytidine deaminase (AID) is involved in somatic DNA alterations of the immunoglobulin gene for amplification of immune diversity. The fact that constitutive expression of AID in mice causes tumors in various organs, including lymphoid tissues and lungs, suggests the important role of the aberrant editing activity of AID on various tumor-related genes for carcinogenesis. AID expression, however, is restricted to activated B cells under physiological conditions. We demonstrate here that ectopic AID expression is induced in response to tumor necrosis factor-a stimulation in cultured human hepatocytes. The proinflammatory cytokine-mediated expression of AID is achieved by IjB kinase-dependent nuclear factor (NF)-jB signaling pathways. Hepatitis C virus, one of the leading causes of hepatocellular carcinoma (HCC), enhanced AID expression via NF-jB activation through expression of viral core protein. The aberrant expression of AID in hepatoma-derived cells resulted in accumulation of genetic alterations in the c-myc and pim1 genes, suggesting that inappropriate expression of AID acts as a DNA mutator that enhances the genetic susceptibility to mutagenesis in human hepatocytes. Our current findings indicate that the inappropriate expression of AID is induced by proinflammatory cytokine stimulation and may provide the link between hepatic inflammation and the development of HCC.
Introduction
A causal association between inflammation and cancer has been proposed in a variety of chronic inflammatory diseases (Balkwill and Mantovani, 2001; Coussens and Werb, 2002) . One of the well-recognized models of inflammation-associated tumor development is human hepatocarcinogenesis, which is closely associated with hepatitis virus-associated chronic liver disease. In fact, epidemiologic studies demonstrate that most human hepatocellular carcinoma (HCC) develops during chronic hepatic inflammation with features of liver cirrhosis or chronic hepatitis (Tsukuma et al., 1993) . On the other hand, human cancer develops by a multistep process occurring through the accumulation of gene alterations that govern cell proliferation, regeneration and apoptosis (Lengauer et al., 1998; Loeb et al., 2003) . Indeed, DNA mutations leading to the activation of oncogenes and/or inactivation of tumor suppressor genes have been reported in hepatoma cells (Thorgeirsson and Grisham, 2002) . The mechanisms of how hepatocytes with underlying chronic inflammation acquire the genetic changes leading to malignant transformation, however, are unknown.
Activation-induced cytidine deaminase (AID) is a member of the cytidine deaminase family (Muramatsu et al., 1999) and is closely related to apolipoprotein B RNA-editing cytidine deaminase 1, which converts cytosine nucleotides to uracils in RNA (Teng et al., 1993) . AID is expressed in activated B cells, especially in germinal centers and induces somatic hypermutation (SHM), untemplated point mutations, at a high frequency of 10 À3 -10 À4 per base pair, into the variable regions of immunoglobulin genes (Muramatsu et al., 2000; Revy et al., 2000; Kinoshita and Honjo, 2001; Honjo et al., 2002) . As overexpression of AID increases the rate of SHM in B-cell lines and AID can attack the non-immunoglobulin genes, tight control of this protein activity appears crucial under physiologic conditions Okazaki et al., 2002 Okazaki et al., , 2003 Yoshikawa et al., 2002; Kinoshita and Nonaka, 2006) . We demonstrated that aberrant AID expression can induce SHM in a nonimmunoglobulin gene in nonlymphoid cells Yoshikawa et al., 2002) , and mice with constitutive expression of AID develop various tumors, including T-cell lymphomas and lung adenomas, suggesting that AID has direct oncogenic potential via the mutagenesis of inappropriate target genes (Okazaki et al., 2003) . Notably, we recently revealed that endogenous AID was significantly upregulated in both HCC and surrounding noncancerous liver tissues with underlying cirrhosis or chronic hepatitis, where only minute AID expression is detectable in normal liver (Kou et al., 2007) . Moreover, both tumor and nontumor liver tissues with hepatitis C virus (HCV) infection exhibited significantly higher expression levels of the AID gene compared with liver tissues of normal control. These findings led to our hypothesis that aberrant expression of AID is present in hepatocytes and might be involved in the enhanced genetic susceptibility to mutagenesis under inflammatory conditions during hepatocarcinogenesis. We demonstrate here that expression of AID is transcriptionally regulated by nuclear factor (NF)-kB in human hepatocytes, allowing it to induce nucleotide alterations in tumor-related genes. The findings thus provide novel insights into the mechanism of genetic mutations during the process of hepatocarcinogenesis and suggest a link between hepatic inflammation and mutagenesis associated with cancer development.
Results

Development of HCC in AID Tg mice
We previously demonstrated that constitutive expression of AID in transgenic (Tg) mice caused both T-cell lymphoma and micro-adenoma in lung alveoli (Okazaki et al., 2003) . In this study, we focused on the impact of AID expression in the liver and thus analysed the liver phenotype of randomly selected AID Tg mice killed between 58 and 84 weeks after birth for pathologic analysis. We found that 4 of 16 (25.0%) Tg mice developed tumors in the liver. Histological examination revealed that those tumors showed a trabecular pattern of growth with focal steatosis, consistent with the morphological appearance of well-differentiated HCC (Figure 1 ). These findings suggested that aberrant expression of AID in the liver can be genotoxic, leading to the development of HCC.
Endogenous AID is induced in response to proinflammatory cytokines in human hepatocytes To determine whether proinflammatory cytokines enhance AID expression in human hepatocytes, we first analysed the expression of endogenous AID transcripts in human hepatoma cell lines by quantitative reverse transcription-polymerase chain reaction (RT-PCR) Figure 2c ). To investigate the TNF-a-mediated induction of AID more precisely, we examined the time course of AID expression by incubating HepG2 cells with TNF-a. AID transcripts were promptly induced, and the peak level was observed 8-10 h after TNF-a treatment (Figure 2d ). Moreover, TNF-a increased the amount of AID transcripts in a dose-dependent manner, whereas the expression of the internal control 18S ribosomal RNA (18S rRNA) gene was constant under all conditions tested (Figure 2e) .
Next, to study the expression of AID protein in hepatocytes, we performed immunoblotting analyses using antibodies specific for human AID (Ta et al., 2003) . To confirm the specificity of the antibodies, we used AID-specific small interference RNA (siRNA) to knock down the expression of endogenous AID. Only . Total RNA was extracted from HepG2 cells after 10 h of treatment with TNF-a (100 ng/ml) or 12 h of treatment with IL-1b (25 ng/ml). Semiquantitative RT-PCR was performed using oligonucleotide primer sets specific for human AID and b-actin. The expression of cIAP1, another TNF-ainducible gene, was also examined as a control. (b) Hep3B and Huh-6 cells were stimulated with TNF-a (100 ng/ml) for 12 h and semiquantitative RT-PCR was performed in each RNA sample using specific primers for AID and b-actin. (c) Human primary hepatocytes were established from surgical specimens of normal liver tissues of patients with metastatic liver tumors. AID transcripts were measured with or without TNF-a (12.5 ng/ml) stimulation for 12 h by quantitative real-time RT-PCR and the expression levels of AID were normalized to 18S rRNA as an endogenous control. (d and e) Time-dependent and dose-dependent effects of TNF-a on AID expression. HepG2 cells were treated with TNF-a (100 ng/ml) for the indicated time points (d) or with various concentrations of TNF-a (0-100 ng/ml) for 8 h (e). Total RNA was extracted from each specimen and subjected to quantitative real-time RT-PCR analyses for AID expression. (f) HepG2 cells were transfected with siRNA targeting AID or control RNA and lysates were prepared from the siRNA-treated cells after stimulation with TNF-a (100 ng/ml) for 24 h. Protein samples were resolved by 15% sodium dodecyl sulfatepolyacrylamide gel electrophoresis. Immunoblotting was performed using antibodies specific for human anti-AID (upper panel) or anti-a-tubulin antibody (a-tub, lower panel). (g) HepG2 cells were treated with TNF-a (100 ng/ml) for 0, 12, 24 or 48 h, followed by immunoblotting using anti-AID antibody (upper panel) or anti-a-tubulin antibody (a-tub, lower panel). (h) The human primary nonneoplastic hepatocyte cell line was treated with TNF-a (100 ng/ml) for 15 h. Immunoblotting was performed using anti-AID antibody (upper panel) or anti-a-tubulin antibody (a-tub, lower panel).
Expression of AID in human hepatocytes via NF-jB Y Endo et al trace amounts of endogenous AID protein were detectable in HepG2 cells without any stimulation. AID protein expression was markedly increased after TNF-a treatment. In contrast, AID protein was not detected in cells treated with AID-targeting siRNA, irrespective of stimulation with TNF-a ( Figure 2f) . A time course study revealed that AID protein expression was detected after stimulation with TNF-a ( Figure 2g ). We further confirmed the proinflammatory cytokinemediated expression of endogenous AID protein in a non-neoplastic primary hepatocyte cell line that retained primary hepatocyte characteristics ( Figure 2h ) (Aly et al., 2007) . Taken together, these data suggest that proinflammatory cytokine signaling induces AID gene expression in human hepatocytes.
AID expression in hepatocytes is achieved through NF-kB activation Our findings that proinflammatory cytokines induced AID transcripts in hepatocytes led us to test whether AID expression is mediated by an NF-kB-dependent mechanism, because both TNF-a and IL-1b activate the transcription factor NF-kB and contribute to the expression and regulation of various genes. Activation of the classical NF-kB pathway converges on IkB kinase complex (IKK), a protein complex composed of two kinase subunits (IKK-a and IKK-b) and a non-catalytic subunit (IKK-g/NF-kB expansion modulator (NEMO)). To clarify whether IKK is involved in TNF-a-mediated AID expression, we examined the effects of wild-type IKK-a and IKK-b on AID expression. The AID expression levels were significantly upregulated in the cells expressing IKK-a, IKK-b or NF-kB RelA protein itself ( Figure 3a) .
Next, we examined the TNF-a-mediated AID expression with NF-kB signaling inhibitors. We found that the NF-kB inhibitory reagents SN50 and MG132 significantly reduced TNF-a-induced NF-kB activation, and pretreatment with SN50 or MG132 almost completely suppressed the TNF-a-induced increase in AID transcripts (Figure 3b ). Furthermore, TNF-a-induced AID protein expression was almost completely abolished by co-production of the super-repressor form of IkBa, a specific NF-kB inhibitor (Figure 3c ). We then used siRNA to reduce the expression of endogenous IKK-g/ NEMO. Transfection of IKK-g-specific siRNA, but not control siRNA, reduced endogenous IKK-g protein levels in HepG2 cells and the lower levels were sustained for at least 3 days. Under these conditions, TNF-a stimulated AID expression in control cells. In contrast, TNF-a failed to elicit an increase in AID protein in cells in which endogenous IKK-g was reduced by siRNA ( Figure 3d ). Taken together, these findings indicate that the induction of AID expression in human hepatocytes by TNF-a is achieved through the activation of NF-kB.
HCV core protein triggers AID expression via NF-kB
Previously, we demonstrated that the HCV core protein has the potential to induce NF-kB activation in human hepatocytes (Marusawa et al., 1999) . Thus, the expression of AID protein was analysed by immunoblotting in the presence or absence of various HCV proteins. There was a significant upregulation of AID protein expression in HepG2 cells transfected with expression plasmid encoding the whole HCV genome (Figure 4a ). Moreover, marked induction of AID was observed in core-producing cells. In contrast, the production of nonstructural viral protein resulted in little change in the expression Effects of the NF-kB inhibitors on TNF-a-induced NF-kB activity and endogenous AID expression. HepG2 cells were transfected with pNF-kB-Luc, followed by the treatment with MG132 (2 mg/ ml) or SN50 (50 mg/ml) for 2 h, and further subjected to TNF-a (100 ng/ml) stimulation for 12 h. Luciferase activities were monitored in each extract and normalized by the activity of Renilla luciferase (left graphs). Total RNA was also isolated from each cell and the expression levels of AID mRNA were measured by quantitative real-time RT-PCR (right graphs). The data present the means of the relative luciferase activity and AID expression in three independent experiments. (c) pcDNA3-IkBaDN was transfected into Hep3B cells and then treated with TNF-a (100 ng/ml) for 24 h. Empty vector was used as a control (CTR). Each sample was harvested and luciferase activities were monitored to quantify the endogenous NF-kB activities. Cell lysates were also probed with anti-AID (upper panel) or anti-a-tubulin (a-tub, lower panel). Lysate from the BL2-lymphoma cell line was used as a positive control (PC). (d) HepG2 cells were transfected with siRNA targeting IKK-g/NEMO for 48 h and then treated with TNF-a (100 ng/ml) for 24 h. Whole-cell lysates were probed by anti-AID antibody (upper panel), anti-IKK-g/NEMO antibody (middle panel) or anti-a-tubulin antibody (a-tub, lower panel). levels of endogenous AID protein. Consistent with the findings of the synergy of proinflammatory cytokine stimulation and viral protein on NF-kB activation (Marusawa et al., 1999) , the treatment of whole HCV protein-or core-producing cells with TNF-a further enhanced the expression of AID expression.
To determine whether HCV core-induced AID expression was achieved in an NF-kB-dependent manner, the effects of NF-kB inhibitors and the superrepressor form of IkBa on AID expression were examined in the viral core-expressing cells. We found that incubation of the cells with NF-kB inhibitors, SN50 and MG132, reduced the expression of AID in the cells expressing the viral protein (Figure 4b) . Moreover, coproduction of the super-repressor form of IkBa with HCV core protein resulted in the reduced expression of endogenous AID protein in HepG2 cells (Figure 4c) .
To further confirm the aberrant upregulation of AID by HCV infection, we analysed the expression levels of endogenous AID in the full-genome HCV replicon cells producing whole HCV RNA and proteins (NNC#2 cells) (Ishii et al., 2006) . Consistent with a previous report, the expression of the HCV core in the replicon cells was confirmed by RT-PCR (Figure 4d ). Immunoblotting analyses revealed that AID protein expression was dramatically enhanced in the full-genome replicon cells compared with that in the parental cells lacking HCV replication (Figure 4e ). These results demonstrate that HCV core protein induces the expression of AID via NF-kB activation in human hepatocytes.
Expression of AID is sufficient to induce nucleotide alterations in the tumor-related genes in human hepatocytes To determine whether aberrant AID expression could contribute to the accumulation of genomic mutations in hepatocytes, we investigated the mutation occurrence in the c-myc and pim1, both of which are thought to be common targets for abnormal editing in the lymphoma cells of AID Tg mice (Kotani et al., 2005) . For this purpose, we established a conditional system that allows for AID activation in the cells in response to an estrogen analog, 4-hydroxytamoxifen (OHT) (Doi et al., 2003) . The OHT treatment triggers a post-translational conformational change and thus prompt activation of AID in AID-estrogen receptor (ER)-expressing cells. When the AID ER-expressing HepG2 cells were treated with OHT for 8 days, we found the emergence of nucleotide alterations in the c-myc and pim1 genes in the cells with AID activation, whereas the mutation frequencies in AID-activating cells did not show a statistically significant difference compared to the frequencies in the cells without AID activation (Figure 5a ). In contrast, none of the nucleotide substitutions was detected in the control cells with OHT treatment. As the c-myc and pim1 genes were found to be the possible targets for AID in HepG2 cells, we asked whether AID could induce genomic mutations in other tumor-related genes, b-catenin and PTEN, both of which are thought to be involved in human hepatocarcinogenesis (Thorgeirsson and Grisham, 2002) . None of the nucleotide alterations, however, were observed in the b-catenin and PTEN genes after the OHT treatment. As it has been shown that the AIDmediated somatic mutation is induced in a transcriptiondependent manner, we examined the expression levels of these four tumor-related genes in HepG2 cells. RT-PCR analyses revealed evidence showing that the transcription levels of b-catenin and PTEN genes were comparable with those of c-myc and pim1 genes (Figure 5b) .
Consistent with the findings observed in cultured human hepatoma-derived cells with AID activation, sequence analyses of HCC tissues of the AID Tg mice revealed that the c-myc gene, which was reported to accumulate high mutation frequencies in T-cell lymphoma, contained nucleotide alteration accompanied by upregulation of c-myc transcripts (Supplementary Figure) . Taken together, these data suggest that the specificity for mutation of target genes is present in hepatocytes, as was observed in T-cell lymphoma cells (Kotani et al., 2005) . 
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Moreover, animal models demonstrate that aberrant expression of AID causes an accumulation of DNA mutations in various genes leading to tumorigenesis (Okazaki et al., 2003; Kotani et al., 2005) . These findings suggest that inappropriate or deregulated AID expression increases the mutation rate of genes that are not normally attacked by AID and are associated with tumor development (Kinoshita and Nonaka, 2006) . Under physiologic conditions, however, basal expression levels of AID are not high and the expression of AID is restricted to activated B cells located at the germinal centers. In this study, we clearly demonstrated for the first time that AID expression in hepatocytes is strongly induced in response to proinflammatory cytokine stimulation via NF-kB activation.
At present, little is known about how AID expression is regulated, except that it is under the control of B-cell activating stimulation. It was shown that CD40 ligation induces NF-kB binding to the two potential NF-kB sites located in the 5 0 upstream region of the AID gene, suggesting that NF-kB participates in the regulatory process of the AID gene in B cells (Dedeoglu et al., 2004) . In this study, we examined the mechanisms of AID regulation by proinflammatory cytokines and demonstrated that NF-kB activation is involved in TNF-a-as well as IL-1b-induced AID gene transcription in hepatocytes. The induction of AID transcripts is regulated in an NF-kB-dependent manner in both human lymphoid and human epithelial cells, which suggests the presence of a common mechanism underlying the regulation of AID gene transcription.
Several proinflammatory cytokines, including TNF-a and IL-1b, play important roles in the pathophysiology of chronic inflammatory disease, including chronic hepatitis (Tilg et al., 1992; Gonzalez-Amaro et al., 1994) . IkB kinase-dependent NF-kB signaling pathways are reported to link inflammation to tumorigenesis (Greten et al., 2004; Pikarsky et al., 2004; Karin and Greten, 2005) . Activation of this pathway leads to increases in a variety of genes that encode mediators of inflammatory cytokines, chemokines, cell adhesion molecules, and apoptosis inhibitors (Pahl, 1999; Balkwill and Mantovani, 2001) . In this study, we identified AID as a target gene of the IKK-b-dependent NF-kB activation pathway in human hepatocytes. A connection between inflammatory stimulation and AID expression led to the speculation that one possible mechanism for increased susceptibility to HCC in the liver during chronic inflammation is inappropriate expression of AID in hepatocytes via NF-kB activation.
An important finding in this study is that HCV infection, one of the major causes of HCC, might trigger Expression of AID in human hepatocytes via NF-jB Y Endo et al aberrant AID expression in hepatocytes. We previously demonstrated that among the HCV proteins, the core protein functioned in the activation of NF-kB and that NF-kB-dependent transcriptional activities induced by TNF-a were synergistically enhanced by the presence of a viral core protein (Marusawa et al., 1999) . Consistent with our previous findings, the TNF-a-induced AID expression was strongly enhanced by the presence of HCV core protein. Interestingly, HCV-associated HCC shows various mutations in proto-oncogenes, but nonviral HCC does not (Machida et al., 2004) . Taken together, these findings suggest that the upregulation of AID induced by HCV infection in chronically damaged liver might contribute to enhanced susceptibility to mutagenesis, resulting in the accumulation of somatic mutations leading to the production of sufficient genomic alterations and eventually to cancer development. In this study, we showed that constitutive and ubiquitous expression of AID in Tg mice caused the development of HCC as well as T-cell lymphoma. Moreover, aberrant AID expression was capable of triggering accumulation of nucleotide alterations in the c-myc gene in cultured hepatoma-derived cells in vitro. It has been demonstrated that deregulation of c-myc has been implicated in the etiology of a wide variety of human cancers (Pelengaris et al., 2002) . The deregulating mutations impact either on the c-myc gene itself or on upstream regulatory sequences, and point mutations or gene amplification of c-myc was reported in human HCC (Feitelson, 2006) . Moreover, several studies revealed that the mouse models with overexpression of c-myc developed liver cancers (Murakami et al., 1993; Coulouarn et al., 2006) . Thus, it is tempting to speculate that increased AID expression might be responsible for the enhanced susceptibility of the hepatocytes to somatic gene alterations in tumor-related genes including c-myc, which might facilitate HCC development. In the current study, however, the c-myc mutation frequency in AID-activating HepG2 cells did not show a statistically significant difference compared with that in the cells without AID activation. It has been supposed that the AID-mediated somatic mutation is induced in a transcription-dependent manner and the preference of target genes is variable between the cells with AID expression (Kotani et al., 2005) . Thus, there is room for further investigation to identify the frequent target genes of AID in human hepatocytes.
In conclusion, our findings provide the first evidence that AID is induced in response to proinflammatory cytokines via the NF-kB/IKK-b signaling pathway and might be responsible for the development of HCC in the underlying chronic liver disease. Understanding the mechanisms of AID upregulation in human hepatocytes might provide a new strategy for preventing the development and progression of HCC in patients with chronic liver disease.
Materials and methods
AID Tg mice
Generation of AID Tg mice was described previously (Okazaki et al., 2003) . Tissue samples from the mice were removed and fixed in 4% (w/v) formaldehyde, embedded in paraffin, stained with hematoxylin and eosin (H&E), and examined for histological abnormalities.
Cell culture and transfection
Human hepatoma-derived cell lines, Hep3B, Huh-6 and HepG2, were maintained in Dulbecco's modified Eagle's medium (Gibco-BRL, Tokyo, Japan) containing 10% fetal bovine serum. For plasmid transfection, we used Trans-IT LT1 transfection reagent (Mirus Bio Corporation, Madison, WI, USA).
siRNA duplexes composed of 21-nucleotide sense and antisense strands used for targeting IKK-g/NEMO and AID were obtained from Dharmacon Research (Lafayette, CO, USA). Transfection of siRNA was described previously .
Primary human hepatocytes were isolated from surgical specimens of patients with metastatic liver tumors undergoing partial hepatectomy (Tateno et al., 2000; Tanaka et al., 2006) , after informed consent for the use of resected tissues was obtained in accordance with the Declaration of Helsinki Principle. An established non-neoplastic human primary hepatocyte cell line that retained primary hepatocyte characteristics was also used (Aly et al., 2007) .
A full genome HCV replicon system was established by transfecting to the cells with the NN strain (genotype 1b) (Ishii et al., 2006) .
A system that allows conditional expression of the active form of AID was established by stable transfection of the HepG2 cells with pAID-ER-BOSbsr vector encoding the active form of AID fused with the hormone-binding domain of the human ER designated as AID-ER (Doi et al., 2003) .
Reagents and antibodies
Recombinant human TNF-a and IL-1b were obtained from Peprotech EC (London, UK) and R&D Systems Inc. (Minneapolis, MN, USA), respectively. NF-kB inhibitors MG132 and SN50 were purchased from Biomol International LP (Plymouth Meeting, PA, USA). Polyclonal antibody against human AID was generated using purified recombinant AID protein as an immunogen (Ta et al., 2003) . Mouse monoclonal antibodies against human IKK-g/NEMO and atubulin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Calbiochem (San Diego, CA, USA), respectively. Plasmids pcDNA3-IkBaDN, for expression of the super-repressor form of the IkB-a protein, was made by inserting the cDNA fragment of human IkB-a into the BamHI-EcoRI sites of pcDNA3 (Invitrogen, Carlsbad, CA, USA). The cDNA fragment for pcDNA3-IkBaDN (amino acids 37-317) was synthesized by RT-PCR with the oligonucleotide primers 5 0 -CGCGGATCCATGAAAGACGAGGAGTACGA-3 0 (forward) and 5 0 -CCGGAATTCTCATAACGTCAGACGCTG GC-3 0 (reverse). The expression plasmids pcDNA3-IKK-a and IKK-b were described previously (Marusawa et al., 2001) . The plasmids for the expression of various HCV proteins, including pCMV-3010 for the expression of full viral proteins, pCMV-core for the expression of the core, and pCMV-NS for the expression of the non-structural protein, were described previously (Marusawa et al., 1999) .
Semiquantitative and quantitative real-time RT-PCR Total RNA was extracted from the cells using Sepasol-RNA 1 Super (Nacalai Tesque, Kyoto, Japan) according to the Expression of AID in human hepatocytes via NF-jB Y Endo et al manufacturer's protocol. For the RT reaction, 1 mg of total RNA was reverse transcribed into 20 ml of cDNA using the Superscript III first-strand synthesis system and oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers (Invitrogen). PCR amplification was performed using Takara Ex Taq DNA polymerase (Takara, Tokyo, Japan). The oligonucleotide primers for the amplification of AID, cIAP1 and HCV-core were as follows: AID, 5 0 -AAATGTCC GCTGGGCTAAGG-3 0 (forward) and 5 0 -GGAGGAAGAGC AATTCCACGT-3 0 (reverse); cIAP1, 5 0 -CTCTGAGGTTTAG CATTTCA-3 0 (forward) and 5 0 -CTCCAGGTCCAAAATGA ATA-3 0 (reverse); HCV-core, 5 0 -TCGTTGGTGGAGTTTAC CTG-3 0 (forward) and 5 0 -GCGGAATGTACCCCATGA-3 0 (reverse). Quantification of gene expression was performed by quantitative real-time RT-PCR using the 7300 Real-Time PCR System (PE Applied Biosystems, Foster City, CA, USA) . The 6-carboxyfluorescein-labeled probe specific for human AID was 5 0 -TCGGCGTGAGACC TACCTGTGCTAC-3 0 . Standard curves for AID were generated for every target using a 10-fold serial dilution series of five independent transcripts derived from BL2-lymphoma cells, which contain a high expression level of endogenous AID. To assess the quantity of isolated RNA as well as the efficiency of cDNA synthesis, target cDNAs were normalized to the endogenous mRNA levels of the housekeeping reference gene 18S rRNA . For simplicity, the ratios were represented as relative values compared with expression levels in a lysate from control cells.
Subcloning and sequencing of the tumor-related genes Genomic DNA from the cultured cells and mouse liver tissues was prepared using the DNeasy Tissue Kit (Qiagen, Tokyo, Japan) according to the manufacturer's protocol.
The oligonucleotide primers for c-myc were designed to amplify the sequences between exon 1 and intron 1 of the human c-myc gene using 5 0 -GCCGAATTCTTGCAGCTGC TTAGACGCTG-3 0 (forward) and 5 The primers for the amplification of the mouse c-myc gene were as follows: 5 0 -GTTAAGCTTGCGTTTTTTTCTGACT CGCTG-3 0 (forward) and 5 0 -GTTGAATTCCCTACCCC AACTACTCTTGA-3 0 (reverse). After the amplification of each gene using high-fidelity Phusion Taq polymerase (FINNZYMES), the PCR products were subcloned by insertion into the pcDNA3 vector and further subjected to sequence analyses as described previously (Marusawa et al., 2000) .
